SELLAS Life Sciences Group (SLS) News Today $1.56 -0.06 (-3.42%) As of 12:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Sellas Life Sciences: Tons Of Completed StudiesJune 17 at 9:41 AM | seekingalpha.comSELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Increase in Short InterestSELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw a large increase in short interest in the month of May. As of May 31st, there was short interest totalling 12,220,000 shares, an increase of 39.5% from the May 15th total of 8,760,000 shares. Based on an average daily volume of 1,910,000 shares, the days-to-cover ratio is presently 6.4 days. Currently, 17.6% of the company's shares are short sold.June 16 at 4:45 PM | marketbeat.comNostrand Robert L. Van Purchases 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) StockJune 14 at 8:41 AM | insidertrades.comNostrand Robert L. Van Acquires 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) StockSELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) Director Nostrand Robert L. Van purchased 10,000 shares of SELLAS Life Sciences Group stock in a transaction on Thursday, June 12th. The stock was bought at an average price of $1.48 per share, with a total value of $14,800.00. Following the completion of the acquisition, the director now directly owns 20,400 shares of the company's stock, valued at approximately $30,192. This trade represents a 96.15% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.June 13, 2025 | marketbeat.comSELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology ExpertsJune 5, 2025 | globenewswire.comSELLAS Life Sciences Presents Preclinical Data on SLS009 as a Targeted Therapy for ASXL1 Mutated Colorectal Cancer at ASCO 2025June 4, 2025 | nasdaq.comInsider Buying: SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Purchases 20,000 Shares of StockSELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) Director Jane Wasman purchased 20,000 shares of the business's stock in a transaction on Friday, May 30th. The stock was purchased at an average cost of $1.69 per share, for a total transaction of $33,800.00. Following the completion of the acquisition, the director now directly owns 30,400 shares of the company's stock, valued at approximately $51,376. The trade was a 192.31% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.June 3, 2025 | marketbeat.comSELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Jane Wasman Buys 20,000 SharesJune 3, 2025 | insidertrades.comSELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual MeetingJune 2, 2025 | globenewswire.com594,919 Shares in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Bought by Brooklyn FI LLCBrooklyn FI LLC acquired a new position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 594,919 shares of the company's stock, valued aMay 28, 2025 | marketbeat.comSELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company ShowcaseMay 20, 2025 | globenewswire.comSellas doses first paediatric subject with AML in Phase II trial of SLS009May 16, 2025 | msn.comSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AMLMay 15, 2025 | finanznachrichten.deSELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AMLMay 15, 2025 | globenewswire.comSELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 13, 2025 | globenewswire.comSELLAS Life Sciences Group (SLS) to Release Earnings on TuesdaySELLAS Life Sciences Group (NASDAQ:SLS) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-13-sellas-life-sciences-group-inc-stock/)May 8, 2025 | marketbeat.comAnson Funds Management LP Has $1.24 Million Holdings in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)Anson Funds Management LP grew its holdings in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) by 50.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,192,266 shares of the company's stock after purcMay 5, 2025 | marketbeat.comSELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR ConferenceApril 28, 2025 | globenewswire.comSELLAS Life Sciences Group (NASDAQ:SLS) Trading 1.6% Higher - Time to Buy?SELLAS Life Sciences Group (NASDAQ:SLS) Shares Up 1.6% - Time to Buy?April 26, 2025 | marketbeat.comSELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2025 | globenewswire.comSellas Life Sciences announces OS data in Cohort 3 from Phase 2 SLS009 trialApril 9, 2025 | markets.businessinsider.comSELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AMLApril 8, 2025 | globenewswire.comSELLAS Life Sciences Group, Inc. Common Stock (SLS) Insider ActivityMarch 30, 2025 | nasdaq.comSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 21, 2025 | finanznachrichten.deSELLAS Life Sciences Group (NASDAQ:SLS) Issues Quarterly Earnings ResultsSELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) posted its earnings results on Thursday. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03.March 21, 2025 | marketbeat.comBrooklyn FI LLC Takes Position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)Brooklyn FI LLC bought a new position in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 594,919 shares of the company's stockMarch 21, 2025 | marketbeat.comSELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 20, 2025 | globenewswire.comSELLAS Life Sciences Group (SLS) to Release Earnings on ThursdaySELLAS Life Sciences Group (NASDAQ:SLS) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comSELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Decrease in Short InterestSELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw a significant decline in short interest in February. As of February 15th, there was short interest totalling 8,650,000 shares, a decline of 11.8% from the January 31st total of 9,810,000 shares. Based on an average daily volume of 2,700,000 shares, the days-to-cover ratio is currently 3.2 days.March 7, 2025 | marketbeat.comSellas reports Phase IIa trial data of SLS009 for DLBCL treatmentFebruary 21, 2025 | msn.comSELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCLFebruary 20, 2025 | finanznachrichten.deSELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trialFebruary 20, 2025 | msn.comSellas Life Sciences’ zanubrutinib combination shows efficacy in DLBCLFebruary 20, 2025 | markets.businessinsider.comSELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCLFebruary 20, 2025 | globenewswire.comInvestors Buy High Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was the target of unusually large options trading on Monday. Stock investors purchased 9,455 call options on the company. This represents an increase of 146% compared to the typical daily volume of 3,838 call options.February 4, 2025 | marketbeat.comSELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw some unusual options trading on Monday. Traders acquired 9,455 call options on the stock. This is an increase of approximately 146% compared to the average volume of 3,838 call options.February 3, 2025 | marketbeat.comSellas $25M registered direct offering priced at $1.27 per share and warrantJanuary 29, 2025 | markets.businessinsider.comSELLAS secures $25 million in registered direct offeringJanuary 28, 2025 | msn.comSELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJanuary 28, 2025 | globenewswire.comPositive Phase 3 Results and Investment Opportunity Highlighted in SELLAS Life Sciences GroupJanuary 25, 2025 | markets.businessinsider.comSellas Life Sciences announces IDMC completed interim analysis of REGAL trialJanuary 24, 2025 | markets.businessinsider.comSellas Says IDMC Recommends Continuation Of REGAL Trial Of GPS In Acute Myeloid LeukemiaJanuary 23, 2025 | markets.businessinsider.comSELLAS Life Sciences falls after data for blood cancer therapyJanuary 23, 2025 | msn.comSELLAS shares tumble on interim trial resultsJanuary 23, 2025 | msn.comSELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid LeukemiaJanuary 23, 2025 | globenewswire.comSELLAS Life Sciences amends executive severance agreementsJanuary 16, 2025 | msn.comSELLAS Life Sciences Amends Severance for Key ExecutivesJanuary 16, 2025 | tipranks.comSELLAS Life Sciences Group, Inc.: SELLAS Announces Key Business Objectives for 2025January 8, 2025 | finanznachrichten.deSELLAS Announces Key Business Objectives for 2025January 8, 2025 | globenewswire.comPromising Phase 2 Results and Strategic Potential Drive Buy Rating for SELLAS Life Sciences’ SLS009December 12, 2024 | markets.businessinsider.com Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address SLS Media Mentions By Week SLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLS News Sentiment▼1.270.90▲Average Medical News Sentiment SLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLS Articles This Week▼71▲SLS Articles Average Week Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Bicara Therapeutics News Autolus Therapeutics News Evolus News Phathom Pharmaceuticals News ChromaDex News Stoke Therapeutics News Upstream Bio News Taysha Gene Therapies News Bicycle Therapeutics News Mind Medicine (MindMed) News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLS) was last updated on 6/17/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
